Published in Thyroid on April 10, 2011
SCF(β-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J Exp Med (2012) 1.18
Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin Cancer Res (2012) 1.14
Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions. Minerva Endocrinol (2012) 1.00
Metastatic mechanisms in follicular cell-derived thyroid cancer. Endocr Relat Cancer (2013) 0.88
Clinical outcome, role of BRAF(V600E), and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer? Front Endocrinol (Lausanne) (2012) 0.84
[Lymph node and distant metastases of thyroid gland cancer : Metastases in the thyroid glands]. Pathologe (2015) 0.76
RCAN1-4 is a thyroid cancer growth and metastasis suppressor. JCI Insight (2017) 0.75
Thyroid Cancer Initially Presenting Compression Fracture without Common Thyroid Symptoms. Ann Rehabil Med (2012) 0.75
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol (2008) 19.86
Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer (2009) 14.17
Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol (2006) 13.29
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell (2009) 13.09
Paradoxical roles of the immune system during cancer development. Nat Rev Cancer (2006) 10.57
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene (2010) 9.66
Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol (2008) 7.30
Exosomes--vesicular carriers for intercellular communication. Curr Opin Cell Biol (2009) 6.96
Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer (2007) 6.58
Hypoxia-inducible factors, stem cells, and cancer. Cell (2007) 5.96
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab (2006) 5.78
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature (2004) 5.61
Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol (2009) 5.44
Seeding and propagation of untransformed mouse mammary cells in the lung. Science (2008) 5.33
BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev (2007) 5.21
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature (2009) 3.93
Prespecification and plasticity: shifting mechanisms of cell migration. Curr Opin Cell Biol (2004) 3.78
Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol (2009) 3.73
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res (2009) 3.56
The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol (2011) 2.83
Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res (2009) 2.68
Microvesicles: messengers and mediators of tumor progression. Cell Cycle (2009) 2.66
Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res (2008) 2.63
Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev (2003) 2.39
Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab (2005) 2.30
High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest (1993) 2.25
Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer (2010) 2.13
Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer (2008) 2.11
Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res (2010) 2.02
Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci U S A (2007) 1.84
Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy. J Natl Cancer Inst (2007) 1.78
Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth. Cancer Cell (2008) 1.72
Extracellular matrix stiffness and architecture govern intracellular rheology in cancer. Biophys J (2009) 1.64
Systemic cancer progression and tumor dormancy: mathematical models meet single cell genomics. Cell Cycle (2006) 1.54
The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res (2009) 1.48
Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am (2008) 1.41
Thyroid cancer and inflammation. Mol Cell Endocrinol (2009) 1.37
Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res (2009) 1.35
Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab (2009) 1.32
Prognostic importance of vascular invasion in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg (2000) 1.28
Metastin receptor is overexpressed in papillary thyroid cancer and activates MAP kinase in thyroid cancer cells. J Clin Endocrinol Metab (2002) 1.24
The role of metastasis suppressor genes in metastatic dormancy. APMIS (2008) 1.21
The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. Clin Endocrinol (Oxf) (2010) 1.17
Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab (2010) 1.13
Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. J Clin Endocrinol Metab (2009) 1.11
Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumor-dormant state. J Immunol (1999) 1.07
Vaccines and immunotherapeutics for the treatment of malignant disease. Clin Dev Immunol (2010) 1.04
KiSS-1/G protein-coupled receptor 54 metastasis suppressor pathway increases myocyte-enriched calcineurin interacting protein 1 expression and chronically inhibits calcineurin activity. J Clin Endocrinol Metab (2005) 0.98
Inhibition of uPAR and uPA reduces invasion in papillary thyroid carcinoma cells. Laryngoscope (2010) 0.96
The Down syndrome critical region gene 1 short variant promoters direct vascular bed-specific gene expression during inflammation in mice. J Clin Invest (2009) 0.94
T cell-mediated help against tumors. Cell Cycle (2008) 0.93
Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion. Endocr Relat Cancer (2010) 0.93
Oncoprotein signaling mediates tumor-specific inflammation and enhances tumor progression. J Immunol (2009) 0.90
Interaction of Duffy antigen receptor for chemokines and KAI1: a critical step in metastasis suppression. Cancer Res (2007) 0.86
Reduced nm 23-H1 messenger RNA expression in metastatic lymph nodes from patients with papillary carcinoma of the thyroid. Am J Pathol (1993) 0.85
Regulator of calcineurin 1 modulates cancer cell migration in vitro. Clin Exp Metastasis (2009) 0.84
Molecular markers of aggressiveness of thyroid cancer. Curr Opin Endocrinol Diabetes Obes (2009) 0.83
Preferential reduction of nm23-H1 gene product in metastatic tissues from papillary and follicular carcinomas of the thyroid. Mod Pathol (1995) 0.80
nm23-H1 immunoreactivity as a prognostic factor in differentiated thyroid carcinoma. J Clin Endocrinol Metab (2001) 0.78